US 12,213,983 B2
Treatment of cancers using PI3 kinase isoform modulators
Howard M. Stern, Waban, MA (US); and Jeffrey L. Kutok, Natick, MA (US)
Assigned to Infinity Pharmaceuticals, Inc., Cambridge, MA (US)
Filed by Infinity Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Apr. 14, 2020, as Appl. No. 16/848,485.
Application 16/848,485 is a continuation of application No. 15/581,414, filed on Apr. 28, 2017, abandoned.
Application 15/581,414 is a continuation of application No. 14/439,965, abandoned, previously published as PCT/US2013/067929, filed on Nov. 1, 2013.
Application 14/439,965 is a continuation in part of application No. 13/840,822, filed on Mar. 15, 2013, abandoned.
Claims priority of provisional application 61/888,454, filed on Oct. 8, 2013.
Claims priority of provisional application 61/863,365, filed on Aug. 7, 2013.
Claims priority of provisional application 61/836,088, filed on Jun. 17, 2013.
Claims priority of provisional application 61/829,168, filed on May 30, 2013.
Claims priority of provisional application 61/767,606, filed on Feb. 21, 2013.
Claims priority of provisional application 61/733,852, filed on Dec. 5, 2012.
Claims priority of provisional application 61/721,432, filed on Nov. 1, 2012.
Prior Publication US 2021/0060022 A1, Mar. 4, 2021
Int. Cl. A61K 31/519 (2006.01); A61K 31/505 (2006.01); A61K 31/52 (2006.01); A61K 31/704 (2006.01); A61K 45/06 (2006.01); C07D 401/12 (2006.01); C07D 471/04 (2006.01); C07D 473/00 (2006.01); C07D 473/34 (2006.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01)
CPC A61K 31/52 (2013.01) [A61K 31/505 (2013.01); A61K 31/519 (2013.01); A61K 31/704 (2013.01); A61K 45/06 (2013.01); C07D 401/12 (2013.01); C07D 471/04 (2013.01); C07D 473/00 (2013.01); C07D 473/34 (2013.01); G01N 33/5011 (2013.01); G01N 33/574 (2013.01); G01N 2333/521 (2013.01); G01N 2333/525 (2013.01); G01N 2333/53 (2013.01); G01N 2333/5434 (2013.01); G01N 2333/9121 (2013.01); G01N 2333/96494 (2013.01)] 19 Claims
 
1. A method of treating a hematologic malignancy in a human subject in need thereof, comprising orally administering to the subject twice daily about 25 mg to about 75 mg of a compound having the following structure or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof:

OG Complex Work Unit Chemistry
wherein the hematologic malignancy is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), CLL/SLL, indolent non-Hodgkin lymphoma (iNHL), peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or follicular lymphoma (FL).